WATCH: A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors

Pharm Stat. 2024 Dec 26. doi: 10.1002/pst.2463. Online ahead of print.

Abstract

This article proposes a Workflow for Assessing Treatment effeCt Heterogeneity (WATCH) in clinical drug development targeted at clinical trial sponsors. WATCH is designed to address the challenges of investigating treatment effect heterogeneity (TEH) in randomized clinical trials, where sample size and multiplicity limit the reliability of findings. The proposed workflow includes four steps: analysis planning, initial data analysis and analysis dataset creation, TEH exploration, and multidisciplinary assessment. The workflow offers a general overview of how treatment effects vary by baseline covariates in the observed data and guides the interpretation of the observed findings based on external evidence and the best scientific understanding. The workflow is exploratory and not inferential/confirmatory in nature but should be preplanned before database lock and analysis start. It is focused on providing a general overview rather than a single specific finding or subgroup with a differential effect.

Keywords: heterogeneous treatment effects; machine learning; subgroup analysis; subgroup identification.

Grants and funding